Good Thursday afternoon, friends and fellow traders (and for some of you, good Friday morning). Regardless of when you read the newsletter, today's edition is going to get your heart rate up a little bit. First things first. Does everybody have a stake in Lexaria Bioscience (LXRP) from our October 27th recommendation? Hope so. Thanks to today's 18% jump, LXRP is up 93% since then and still seems to be going strong. And we love the way the chart's taken shape of late. The bullishness from mid-December was on strong and growing volume. That effort petered out last week and early this week, but note how volume was waning the whole time. Then notice how all that volume came roaring back the past two days. It says there have been and continue to be more buyers than sellers. As for what rekindled the rally, there's little doubt that today's news played a big part of it. The company was co-developing a new health supplement with an established name in the business... NeutriSci International (NU). It and Lexaria were specifically developing a tablet that not only delivered pterostilbene [Google it if you want to be amazed] to a user, but also delivered cannabidiol [Google that too, if you want to be blown away by its benefits]. This double-barreled supplement is sure to turn heads within the health-conscious market, as it may well be the one of the most impressive and most helpful nutritional supplements... ever. The company's press release didn't say when exactly the new product would be on store shelves. As Bryan Murphy said in his commentary at the website today, there are still a few details the company needs to work out. The testing phase is done though. Success. The joint venture is looking forward to moving ahead. As a refresher, the value Lexaria Bioscience brings to the table is a science that makes the CBD in hemp oil more likely to be ingested or absorbed into the human body. Most of it consumed by normal channels, as an edible, is ultimately wasted, bypassing the stomach and intestines. Lexaria has found a way to infuse CBD with a lipid, however, which drastically improves how well the human body absorbs it and makes use of all its healing properties. While the new supplement/tablet makes good use of Lexaria's infusion platform, it's just one of a myriad of ways that know-how can be utilized. The market is starting to see the potential, hence the recent bullishness from LXRP including today's. Thursday also brought news not from, but about, Staffing 360 Solutions (STAF). Ever heard of Greenridge Global Equity Research? We've talked about them before, but if you've forgotten, they do a lot of small cap and micro cap research. Greenridge has been following Staffing 360 Solutions for a while now, and reiterated its opinion and price target on STAF today. It thinks Staffing 360 Solutions shares are worth $3.00 apiece. That's about 320% higher than where the stock is priced today. We'd be the first to acknowledge that seems like a wildly high target. Then we think about the fact that this is a $6.5 million company that's generated about $190 million worth of revenue over the course of the past twelve months. Then we think about the fact that net income is in sight. Then we read how Greenridge came up with the number, and it makes perfect sense. If you want to read the research -- or even just the price-target rationale -- you can do both just by heading over to Bryan Murphy's discussion of the news today. Finally, we just want to let you know if you're not yet a member of the Under the Radar Movers service, you missed out on a whopper of a trade today. The URM crowd just locked in a 100% gain on Delta Technology (DELT) position. Here's the crazy part - James Brumley and his crew only recommended DELT yesterday. Yes, you read and saw that right. The Under the Radar Movers booked a 100% gain on a stock trade held for just one day. Now, let's not be unrealistic. Not every trade moves that far, that fast. On the other hand, the URM team seems able to find more than its fair share of fast movers. A week and a half ago the newsletter booked a 50% gain on Cartesian (CRTN). That trade took less than four weeks to get there. Back in November, the Under the Radar Movers crowd booked a 100% gain on Heat Biologics (HTBX). That trade was only in motion for a week. Just a few days before that, Brumley banked a 63% gain on Rxi Pharmaceuticals (RXII) in less than a week. I asked him how he's finding all these winners so often. He just smiled and gave me a wink. I took that as "I'll never tell." So, if you want to start experiencing some of these ridiculous winners for yourself, the only way to do it is by signing up for the Under the Radar Movers service. Of course, for less than a buck a day, you really can't afford not to. A bunch of people just paid for an entire year's subscription (and then some) with the 100% score on Delta Technology. Your call. Here's how to get it.